Luxin Pharmaceutical reaches a $90 million deal with AstraZeneca Pharmaceuticals regarding Mirabegron patent dispute

LootboxPhobia · 2026-02-10T14:47:07+00:00

Laxin Pharmaceuticals of India has reached a settlement with Japan's Astellas Pharma to resolve patent disputes over the bladder control drug Mirabegron, allowing Laxin to continue selling the product in the United States. Laxin will pay a settlement amount of $90 million, and although it is expected to impact profits in the short term, it provides a clearer path for future profitability.

LootboxPhobia

2026-02-10 14:47:07

Abstract generation in progress

Investing.com – Lupin has reached a settlement with Astellas Pharma of Japan, resolving patent infringement disputes over the bladder control drug Mirabegron, allowing Lupin to continue selling the product in the U.S. market.

According to a stock exchange filing, Lupin and its U.S. subsidiary will pay Astellas a total of $90 million. This includes a $75 million upfront option payment and undisclosed milestone licensing fees based on Mirabegron sales through September 2027.

The agreement ends a pending lawsuit between the two companies disclosed in April 2025.

Mirabegron is considered a key product for Lupin, contributing most of its revenue in the U.S. While the settlement and ongoing costs are expected to impact short-term profitability, it provides a clearer path for future profits.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.